Who Are We to Judge?
This is a constant feature of violence, where young and old alike are released after violent acts only to commit ...
How Medicare Advantage Plans Game the System
There has been concern about how these plans manipulate Medicare reimbursements by adjusting the coding density of the superbills.
Two Headed Monster Returns
The first “head” is the DEA Production Quotas. The second “head” is the 41 State Attorneys General’s nationwide opioid settlement.
Wrongful Prosecution of Dr. Richard Paulus
Fifteen years ago, an “anonymous” person contacted the federal authorities and said that Dr. Richard Paulus was committing fraud.
Health Startups: Manage Expectations
Whenever you work with or hire people, it is almost always a good idea to set and clarify expectations for ...
How to Regulate Healthcare When We Can’t Define it?
The regulation of healthcare is a complex and multifaceted issue that requires careful consideration of key procedures and conditions.
Semaglutide: Keeps Getting Better
Are all these benefits of semaglutide and tirzepatide legitimate or are the clinical studies exaggerating the benefits?
The Overdose Crisis Gets Worse
Opioid addiction doesn’t get as many headlines as it used to, but the crisis is as bad as ever. It ...
Tips to Inject Kindness in Medicine
By incorporating kindness into your clinical encounters, you can greatly enhance the overall patient experience.
Anatomy of a Physician Prosecution
How does the federal government get members of a grand jury to indict an innocent doctor? It turns out to ...
Biden’s Stance on Medical Costs and Abortion
President Biden highlighted key points on health policy during his State of the Union address. His comments impact health policy ...
Closing the Health Startup Divide
The digital transformation strategists tell us that it requires cultural change, process improvement, technology, and workforce upskilling.
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
The IRA’s Drug Negotiation Mechanism Meets the Rebate Industrial Complex
-
Growth Hormone Secretagogues and the Longevity Trade-Off
-
Retatrutide: The Weight Loss Drug Everyone Wants—But Can’t Officially Get
-
The Second Reader That Never Sleeps: Large Language Models and Clinical Decision-Making
-
GLP-1 Agonists Beyond Obesity: The Expanding Therapeutic and Optimization Frontier
